Last reviewed · How we verify
Gemcitabine with R115777
Gemcitabine with R115777 is a Nucleoside analog + farnesyltransferase inhibitor combination Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 3 development for Pancreatic cancer, Advanced solid tumors.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways. Used for Pancreatic cancer, Advanced solid tumors.
At a glance
| Generic name | Gemcitabine with R115777 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Nucleoside analog + farnesyltransferase inhibitor combination |
| Target | Ribonucleotide reductase (gemcitabine); farnesyltransferase (R115777) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine acts as a deoxycytidine analog that is incorporated into DNA, causing chain termination and inhibiting ribonucleotide reductase to deplete deoxyribonucleotides. R115777 inhibits farnesyltransferase, preventing the post-translational modification and membrane localization of Ras proteins, which are frequently mutated in pancreatic and other cancers. The combination targets both DNA synthesis and oncogenic signaling pathways.
Approved indications
- Pancreatic cancer
- Advanced solid tumors
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Fatigue
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer (PHASE2)
- Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (PHASE1, PHASE2)
- Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (PHASE2)
- Combination Chemotherapy in Treating Patients With Advanced Cancer (PHASE1)
- Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine with R115777 CI brief — competitive landscape report
- Gemcitabine with R115777 updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Gemcitabine with R115777
What is Gemcitabine with R115777?
How does Gemcitabine with R115777 work?
What is Gemcitabine with R115777 used for?
Who makes Gemcitabine with R115777?
What drug class is Gemcitabine with R115777 in?
What development phase is Gemcitabine with R115777 in?
What are the side effects of Gemcitabine with R115777?
What does Gemcitabine with R115777 target?
Related
- Drug class: All Nucleoside analog + farnesyltransferase inhibitor combination drugs
- Target: All drugs targeting Ribonucleotide reductase (gemcitabine); farnesyltransferase (R115777)
- Manufacturer: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Pancreatic cancer
- Indication: Drugs for Advanced solid tumors
- Compare: Gemcitabine with R115777 vs similar drugs
- Pricing: Gemcitabine with R115777 cost, discount & access